Brief: Savara Announces Encore Presentations Of Results From Phase 3 IMPALA-2 Clinical Trial Of Molgramostim Inhalation Solution

Savara

02/10/2025 21:28

Oct 2 (Reuters) - Savara Inc SVRA.O:

SAVARA ANNOUNCES ENCORE PRESENTATIONS OF RESULTS FROM THE PHASE 3 IMPALA-2 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT CHEST 2025

Source text: ID:nBw686Ljqa

Further company coverage: SVRA.O

 ((Reuters.Briefs@thomsonreuters.com;))